Optimal management of bleeding complications after cardiac surgery

Seminars in Cardiothoracic and Vascular Anesthesia

Volumn 5, Issue 3, 2001, Pages 217-228

  Skubas, N J ^a   Despotis, G J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; DESMOPRESSIN; HEPARIN; PROTAMINE;

ARTICLE; BLEEDING; BLEEDING DISORDER; BLOOD; BLOOD CLOTTING; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; COST OF ILLNESS; COST UTILITY ANALYSIS; EVALUATION; HEALTH CARE COST; HEALTH CARE SYSTEM; HIGH RISK PATIENT; HUMAN; OPERATION DURATION; PATIENT CODING; REOPERATION; RISK FACTOR; THROMBOCYTE;

EID: 0034824276     PISSN: 10892532     EISSN: None     Source Type: Journal    
DOI: 10.1053/scva.2001.26127     Document Type: Article

References (91)

1. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: A multivariate analysis in cardiac surgical patients
2. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations
3. Reexploration for hemorrhage following coronary artery bypass grafting: Incidence and risk factors
4. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation
5. Blood conservation in coronary artery surgery
6. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: A randomized clinical trial
7. Medical progress: Transfusion medicine-blood transfusion
8. Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation
9. Effect of skin temperature on platelet function in patients undergoing extracorporeal bypass
10. Bleeding complications associated with cardiopulmonary bypass
11. The stratification of cardiac surgical procedures according to use of blood products: A retrospective analysis of 1480 cases
12. Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss
13. Blood use in emergency coronary artery bypass after receipt of abciximab during angioplasty
14. Emergency coronary bypass grafting for failed percutaneous coronary artery stenting: Increased costs and platelet transfusion requirements after the use of abciximab
15. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations
16. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery
17. Coronary artery bypass surgery within 12 hours of administration of abxicimab remains safe despite an increased risk of perioperative bleeding
18. Abciximab and bleeding during coronary artery surgery: Results from the EPILOG and EPISTENT trials
19. Bleeding with coronary artery bypass surgery (CABG) in patients treated with a platelet glycoprotein IIb/IIIa inhibitor
20. Integrelin prevents prolonged bleeding times after cardiopulmonary bypass
21. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass
22. Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment F1 + 2
23. The role of the protein C-thrombomodulin system and fibrinolysis during cardiovascular surgery: Influence of acute preoperative plasmapheresis
24. Activation of coagulation and fibrinolysis during cardiothoracic operations
25. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers
26. Retransfusion of suctioned blood during cardiopulmonary bypass impairs hemostasis
27. Decreased platelet number and function and increased fibrinolysis contribute to postoperative bleeding in cardiopulmonary bypass patients
28. Changes in coagulation and fibrinolysis occurring in dogs during hypothermia
29. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT
30. Cardiopulmonary bypass. Associated hemostatic abnormalities
31. Coagulation and fibrinolysis system in aortic surgery under deep hypothermic circulatory arrest with aprotinin: The importance of adequate heparinization
32. Heparin
33. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass
34. Inhibition of platelet function by heparin. An etiologic factor in postbypass hemorrhage
35. Interaction of protamine sulfate with thrombin
36. Protamine attenuates agonist induced platelet signaling/adhesion molecule expression
37. Does protamine reversal of heparin affect platelet function?
38. The effects of heparinase 1 and protamine on platelet reactivity
39. Reduced protamine dosage for heparin neutralization in open-heart operations
40. Successful use of a reduced dose of protamine after cardiopulmonary bypass
41. Haemostasis disorders in open heart surgery with extracorporeal circulation. Importance of the platelet function and the heparin neutralization
42. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations
43. Hypothermia-induced reversible platelet dysfunction
44. In vitro hypothermia enhances platelet GPIIb-IIIa activation and P-selectin expression
45. Temperature dependence of plasmin-induced activation or inhibition of human platelets
46. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro
47. Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery
48. Mediastinal bleeding after cardiac surgery: Etiologies, diagnostic considerations, and blood conservation methods
49. Bleeding after cardiopulmonary bypass
50. The clinical importance of acquired abnormalities of platelet function
51. Changes in blood coagulation during and following cardiopulmonary bypass: Lack of correlation with clinical bleeding
52. Hemostasis changes during cardiopulmonary bypass surgery
53. The hemostatic response to open-heart operations
54. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: An update
55. Postoperative bleeding in cardiovascular surgery. Does heparin rebound really exist?
56. Heparin-protamine complexes in the production of heparin rebound and other complications of extracorporeal bypass procedures
57. Heparin binding proteins. Contribution to heparin rebound after cardiopulmonary bypass
58. Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic and anticoagulant effects of heparin and dermatan sulfate
59. Management of postoperative heparin rebound following cardiopulmonary bypass
60. Heparin management protocol for cardiopulmonary bypass influences postoperative heparin rebound but not bleeding
61. Control of heparinization by activated clotting time during bypass with improved postoperative hemostasis
62. DDAVP's shortening of the bleeding time seems due to plasma von Willebrand factor
63. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs
64. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial
65. The effect of desmopressin on reducing blood loss in cardiac surgery: A meta-analysis of double-blind, placebo-controlled trials
66. Influence of desmopressin acetate on homologous blood requirements in cardiac surgical patients pretreated with aspirin
67. Use of desmopressin acetate to reduce blood transfusion requirements during cardiac surgery in patients with acetylsalicylic-acid-induced platelet dysfunction
68. The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations
69. Drugs to minimize perioperative blood loss in cardiac surgery: Meta-analyses using perioperative blood transfusion as the outcome
70. Treatment of severe platelet dysfunction and hemorrhage after cardiopulmonary bypass: Reduction in blood product usage with desmopressin
71. The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification
72. DDAVP reduces blood loss and transfusion in cardiac surgical patients with impaired platelet function identified using a point-of-care test: A double blind, placebo controlled trial
73. Effective hemostasis in the cardiac surgical patient: Current status
74. The variability of transfusion practice in coronary artery bypass surgery
75. Alteration of coagulation and selected clinical chemistry parameters in patients undergoing open heart surgery without transfusions
76. Controlled trial of routine administration of platelet concentrates in cardiopulmonary bypass surgery
77. Consensus conference. Platelet transfusion therapy
78. Consensus conference. Fresh-frozen plasma. Indications and risks
79. Approach to the bleeding patient
80. Management of coagulopathy associated with cardiopulmonary bypass
81. Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients
82. Guidelines for transfusion support in patients undergoing coronary artery bypass grafting
83. Hemostasis in massively transfused trauma patients
84. Blood plasma products
85. Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient
86. The effect of an intraoperative treatment algorithm on physicians' transfusion practice in cardiac surgery
87. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery
88. Coagulation dysfunction after cardiopulmonary bypass
89. Anticoagulation monitoring during cardiac surgery. A review of current and emerging techniques
90. Montoring hemostasis with cardiac surgery: The impact of point-of-care testing on blood loss and transfusion outcomes